CIBER-BBN’s exploitable technology patent portfolio is available to companies and organizations to promote its transfer to the industrial sector, generate collaborative technological development projects and favour the use of the research results.
Each of the “technological specification sheets” describes a technology, its industrial application and innovative advantages, among other aspects. Said information can be expanded through the contact shown in each of them.
CIBERER is making available its technologyl range of patents to be exploited:
Here you will find our offers and requests for technology that are available for collaboration with companies. If you need any further information or have a particular technological issue to address, please contact us at firstname.lastname@example.org. We are open to different kinds of collaboration.
4. Quick method to assess if different isolates of M. Tuberculosis have the same clone origin and if they are resistant to rifampicin and isoniazid
Based in IS6110 (Gold standard), offers quick results (few hours), is automated, standardized and reproducible. If widely adopted, this technology would allow better control of TB. The technology can be used to identify strains resistant to rifampicin and isoniazid and can be extended to other bacteria with specific IS.
7. Test for predicting blood pressure response to continuous positive air pressure treatment (CPAP) in patients with resistant hypertension
A test based in a set of miRNAs which expression in plasma can predict blood pressure response to CPAP treatment for patients with resistant hypertension that do not respond to any other treatment. This method can identify, with high sensitivity and specific values, patients that can positively benefit from CPAP treatment for their resistant hypertension.
8. High reliability prediction of fluid/vascular responses and estimation of pleural pressure changes in patients
The non-invasive method allows the prediction of patient's response to intravenous administration of fluid or to evaluate the state of arterial tone or the change of pleural pressure due to respiration. It allows the optimization of hemodynamic monitoring. This evaluation can be carried out in patients under mechanical ventilation or in punctual monitoring, even in patients with cardiac or respiratory arrhythmias.
9. Biomarkers to identify grades of asthma severity in patients.
This set of biomarkers allows the identification of patients at risk of developing asthma, as well as the degree to which it occurs in asthmatic individuals. This can be done regardless of the asthmatic endotype and the inflammatory pathway involved. The method offers high reliability in blood samples. The test allows a very objective diagnosis / prognosis independently of patients and professionals expertise helping in treatment decisions.
10. Differential diagnosis of non-tuberculous mycobacteria.
Method based in detection of immune response against non-TB mycobacteria by specific antigens in blood. It can be used for the differential diagnosis of NTM infections vs. tuberculosis (TB) infections or latent TB infection, allowing a more accurate diagnosis of latent TB particularly in the pediatric population (unmet need). This diagnosis is important in : pulmonary infections, lymphadenitis and skin and soft tissue infections, and specifically in: children diagnosed with cystic fibrosis, in patients suffering from chronic respiratory diseases, including chronic obstructive pulmonary disease (COPD) or in immunosuppressed adults.
11. Detection of Tuberculosis in urine samples by a specific metabolic signature.
A set of metabolic biomarkers, whose relative level can diagnose tuberculosis in urine samples. A quick and non invasive method to identify and classify patients with a high specificity and sensitivity and with a tuberculosis predictive value of 100%.
In this area you can consult our technology supply and demand available for cooperation with business.
CIBEROBN has the following Technology Range available for you:
Technology range of the CIBEREHD: